drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
An antibody–drug conjugate consisting of a humanized anti-B7-H3 (CD276) IgG1 monoclonal antibody linked via a cleavable linker to a deruxtecan (DXd) topoisomerase I inhibitor payload. After binding B7-H3 on tumor cells and internalization, the linker is cleaved to release DXd, inducing DNA damage and apoptosis with potential bystander effect; the antibody may also mediate Fc-dependent ADCC/ADCP.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Antibody-Drug Conjugates
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Ifinatamab deruxtecan is a B7-H3–targeted antibody–drug conjugate. After binding B7-H3 on tumor cells and internalization, a cleavable linker releases the deruxtecan (DXd) topoisomerase I inhibitor payload, causing DNA damage and apoptosis. The membrane-permeable payload can produce a bystander effect, and the IgG1 antibody may also mediate Fc-dependent ADCC/ADCP.
drug_name
Ifinatamab deruxtecan (I-DXd; DS-7300a)
nct_id_drug_ref
NCT06330064